Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use—A Prospective Real-Life Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use—A Prospective Real-Life Study ; volume:31 ; number:5 ; day:29 ; month:1 ; year:2024 ; pages:2892-2901 ; date:5.2024
Annals of surgical oncology ; 31, Heft 5 (29.1.2024), 2892-2901, 5.2024
- Urheber
-
Paiella, Salvatore
Malleo, Giuseppe
Lionetto, Gabriella
Cattelani, Alice
Casciani, Fabio
Secchettin, Erica
De Pastena, Matteo
Bassi, Claudio
Salvia, Roberto
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1245/s10434-024-14951-4
- URN
-
urn:nbn:de:101:1-2406211159206.467020418321
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Paiella, Salvatore
- Malleo, Giuseppe
- Lionetto, Gabriella
- Cattelani, Alice
- Casciani, Fabio
- Secchettin, Erica
- De Pastena, Matteo
- Bassi, Claudio
- Salvia, Roberto
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Upfront surgical resection for primary bone tumors: rationale and potential benefits
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma
Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Upfront surgical resection for primary bone tumors: rationale and potential benefits
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma
Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Upfront surgical resection for primary bone tumors: rationale and potential benefits
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature